国际妇产科联盟《妊娠滋养细胞疾病诊治指南（2025）》解读

王丽娟; 李睿歆; 贾郑懿; 林仲秋

doi:10.19538/j.fk2025100111

PDF(907 KB)

中国实用妇科与产科杂志 ›› 2025, Vol. 41 ›› Issue (10) : 1012-1017. DOI: 10.19538/j.fk2025100111

指南解读

国际妇产科联盟《妊娠滋养细胞疾病诊治指南（2025）》解读

作者信息 +

文章历史 +

导出引用

王丽娟, 李睿歆, 贾郑懿, 等. 国际妇产科联盟《妊娠滋养细胞疾病诊治指南（2025）》解读[J]. 中国实用妇科与产科杂志. 2025, 41(10): 1012-1017 https://doi.org/10.19538/j.fk2025100111

中图分类号： R737.3

参考文献

列表( 原文顺序 | 文献年度倒序 | 文中引用次数倒序 ) 可视化分析

[1]	王丽娟, 李睿歆, 林仲秋. 2021 FIGO《妊娠滋养细胞疾病诊治指南》解读[J]. 中国实用妇科与产科杂志, 2022, 38(2):181-185. DOI:10.19538/j.fk202202113. 本文引用 [11]

[2]	王丽娟, 凌小婷, 黄晓欣, 等. 《EOTTD-ESGO-GCIG-ISSTD妊娠滋养细胞疾病诊治实践指南》解读[J]. 中国实用妇科与产科杂志, 2025, 41(8):830-835.DOI:10.19538/j.fk2025080113. 本文引用 [1]

[3]

Kohorn

, Goldstein

, Hancock

, et al. Workshop Report: Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Heath Organization for Trophoblastic Neoplasia. Report of the Working Committee of the International Society for the Study of Trophoblastic Disease and the International Gynecologic Cancer Society[J]. Int J Gynecol Cancer, 2000, 10(1):84-88. DOI:10.1046/j.1525-1438.2000.00002.x

本文引用 [1]

[4]	Kohorn EI. The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessment[J]. Int J Gynecol Cancer, 2001, 11,73-77. DOI:10.1046/j.1525-1438.2001.011001073.x. 本文引用 [1]

[5]	Ngan HY, Seckl MJ, Berkowitz RS, et al. Update on the diagnosis and management of gestational trophoblastic disease[J]. Int J Gynecol Obstet, 2018, 143(Suppl 2):79-85. DOI:10.1002/ijgo.12615. 本文引用 [1]

[6]	Ngan HY, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update[J]. Int J Gynecol Obstet, 2021, 155(Suppl 1):86-93. DOI:10.1002/ijgo.13877. 本文引用 [1]

[7]	中国抗癌协会妇科肿瘤专业委员会. 妊娠滋养细胞疾病诊断与治疗指南(2021年版)[J]. 中国癌症杂志, 2021, 31(6):520-532. DOI:10.19401/j.cnki.1007-3639.2021.06.10. 本文引用 [1]

[8]	Lok C, van Trommel N, Massuger L, et al. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease[J]. Eur J Cancer, 2020, 130:228-240. DOI:10.1016/j.ejca.2020.02.011. 本文引用 [1]

[9]

Lok

, van Trommel

, loana Braicu

, et al. Practical guidelines for the treatment of gestational trophoblastic disease: collaboration of the European Organisation for the treatment of trophoblastic disease (EOTTD)-European Society of Gynaecologic Oncology (ESGO)-Gynecologic Cancer InterGroup (GCIG)-International Society for the study of Trophoblastic Disease (ISSTD)[J]. J Clin Oncol, 2025, 43(18):2119-2128. DOI:10.1200/JCO-24-02326.

本文引用 [1]

[10]	Yu H, Li J, Zhu T, et al. Evaluation and influence of lung metastasis on patient outcome in gestational trophoblastic neoplasia: A 10-year study at a single institution[J]. Eur J Obstet Gynecol Reprod Biol, 2020, 251:162-166. DOI:10.1016/j.ejogrb.2020.05.046. 本文引用 [1]

[11]	Yang J, Xiang Y, Wan X, et al. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment[J]. Gynecol Oncol, 2006, 103:479-482. DOI:10.1016/j.ygyno.2006.03.015. 本文引用 [1]

[12]	Powels T, Savage P, Short D, et al. Residual lung lesions after completion of chemotherapy for gestational trophoblastic neoplasia: should we operate?[J] Br J Cancer, 2006, 94:51-54. DOI:10.1038/sj.bjc.6602899. 本文引用 [2]

[13]	Frijstein MM, Lok C, van Trommel NE, et al. Lung metastases in low-risk gestational trophoblastic neoplasia: a retrospective cohort study[J]. BJOG, 2020, 127:389-395.DOI:10.1111/1471-0528.16036. 本文引用 [1]

[14]	Vree M, van Trommel N, Kenter G, et al. The influence of lung metastases on the clinical course of gestationla trophoblastic neoplasia: a historical cohort study[J]. BJOG, 2016, 123:1839-1845. DOI:10.1111/1471-0528.13622. 本文引用 [1]